Catalyst Pharmaceuticals price target raised to $31 from $29 at Oppenheimer
Oppenheimer raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $31 from $29 and keeps an Outperform rating on the shares.
Catalyst Pharmaceuticals price target raised to $35 from $30 at H.C. Wainwright
H.C. Wainwright analyst Andrew Fein raised the firm’s price target on Catalyst Pharmaceuticals (CPRX) to $35 from $30 and keeps a Buy rating on ...
New device harnesses microwave flow reaction to convert biomass into useful sugars
Researchers at Kyushu University have developed a device that combines a catalyst and microwave flow reaction to efficiently ...
MM&M22h
Rx Rundown: Verdiva, Johnson & Johnson, Transcarent and more
Johnson & Johnson received Priority Review of nipocalimab in generalized myasthenia gravis. GSK’s B7-H3-targeted ...
Hippocratic AI secures $141m in Series B funding
Healthcare-focused AI startup Hippocratic AI has closed its Series B financing round, raising $141m, led by venture capital ...
Investor's Business Daily on MSN4h
Stocks Generating Improved Relative Strength: Alnylam Pharmaceuticals
Alnylam Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating ...
marketinference10h
Catalyst Pharmaceuticals Settles Patent Dispute
Catalyst Pharmaceuticals, Inc. has announced a settlement agreement with Teva Pharmaceuticals, resolving the patent ...
Investor's Business Daily on MSN4h
Alkermes Shows Rising Relative Price Performance; Still Shy Of Key Benchmark
Rating on Friday, rising from 69 to 74. Please watch the video at Investors.com - How To Find Game-Changing Stocks This proprietary rating tracks technical performance by showing how a stock's price ...
MyJoyOnline13h
Government must prioritise salt development to grow economy – MIIF Board Chair
Professor Douglas Boateng, Board Chairman of the Minerals Income Investment Fund (MIIF), has underscored the potential of ...